Oruka Therapeutics (NASDAQ:ORKA) Receives “Buy” Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $45.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 116.76% from the company’s current price.

Other research analysts also recently issued reports about the stock. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 price target on the stock. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. TD Cowen started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating on the stock. Lifesci Capital began coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective on the stock. Finally, Leerink Partners started coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 target price for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Stock Down 2.7 %

Shares of NASDAQ:ORKA opened at $20.76 on Friday. The company has a market cap of $726.58 million, a PE ratio of -3.32 and a beta of 0.78. The business has a 50 day simple moving average of $24.67. Oruka Therapeutics has a twelve month low of $18.20 and a twelve month high of $53.88.

Institutional Trading of Oruka Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth $17,661,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter worth about $343,000. Frazier Life Sciences Management L.P. bought a new position in Oruka Therapeutics during the third quarter valued at approximately $11,699,000. Wellington Management Group LLP bought a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $2,013,000. Finally, RTW Investments LP purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $45,359,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.